Drugs / Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02993757 | Dec 2016 → May 2019 | Dengue hemorrhagic fever, human papilloma virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02993757 ↗ |
| Modality | Vaccine | “quadrivalent HPV vaccine” PMID 34250977 ↗ Aug 2021 |
| Route | Intramuscular | “0.5 mL, IM injection at Day 0 and Month 6, respectively.” NCT02993757 ↗ |